Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Magdeburg – page 12

251 clinical trials in Magdeburg, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Magdeburg at a glance
251
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

251 trials in Magdeburg

Open in trial search

Hypertriglyceridaemia

Not recruiting

Study to Evaluate Plozasiran for Adults with High Triglycerides

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Vitiligo

Not recruiting

Study of ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Eosinophilic oesophagitis

Not recruiting

Study on the Effectiveness and Safety of Barzolvolimab in Adults with Active Eosinophilic Esophagitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Asthma

Not recruiting

Study on the Safety of CHF5993 Inhaler with HFA-152a vs. HFA-134a in Patients with Moderate to Severe Asthma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:Chiesi Farmaceutici S.p.A.

Back pain

Not recruiting

Study on the Effects of VER-01, Ibuprofen, and Paracetamol for Patients with Chronic Non-Specific Low Back Pain

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dronabinol
  • Sponsor:Vertanical GmbH

Psoriatic arthropathy

Not recruiting

Study on Izokibep for Improving Symptoms in Patients with Active Psoriatic Arthritis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Izokibep
  • Sponsor:Acelyrin Inc.

Chronic obstructive pulmonary disease

Not recruiting

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Astegolimab
  • Sponsor:F. Hoffmann-La Roche AG

Chronic kidney disease

Not recruiting

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Type 2 diabetes mellitus

Not recruiting

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Magdeburg

What the registry says about research in the country

01 Oncology Research

Clinical investigations focusing on innovative treatments for various cancer types, including breast cancer, lymphoma, and pancreatic cancer. Studies evaluate new therapeutic approaches and combination treatments.

  • HER2-positive metastatic breast cancer therapies
  • Diffuse Large B-Cell Lymphoma treatments
  • Advanced pancreatic cancer interventions

Particular emphasis on targeted therapies and immunotherapy approaches for better patient outcomes.

02 Dermatology Studies

Research focusing on chronic skin conditions and innovative treatments for psoriasis and other dermatological disorders. Multiple trials investigating new therapeutic options.

  • Moderate to severe plaque psoriasis
  • Prurigo nodularis treatments
  • Lichen simplex chronicus management

Studies aim to improve quality of life through advanced therapeutic approaches.

03 Cardiovascular and Metabolic Research

Investigations into treatments for cardiovascular disease and metabolic disorders, including innovative approaches for managing hypertriglyceridemia and diabetes.

  • Cardiovascular risk reduction
  • Type 2 diabetes management
  • Lipid disorder treatments

Focus on preventive strategies and novel therapeutic interventions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.